DE4010536A1 - Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure - Google Patents

Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure

Info

Publication number
DE4010536A1
DE4010536A1 DE4010536A DE4010536A DE4010536A1 DE 4010536 A1 DE4010536 A1 DE 4010536A1 DE 4010536 A DE4010536 A DE 4010536A DE 4010536 A DE4010536 A DE 4010536A DE 4010536 A1 DE4010536 A1 DE 4010536A1
Authority
DE
Germany
Prior art keywords
ethyl
pharmaceutical solution
solution
benzenesulfonylamino
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE4010536A
Other languages
German (de)
English (en)
Other versions
DE4010536C2 (https=
Inventor
Heinrich Dr Rer Nat Woog
Werner Gruber
Werner Heller
Fritz Dr Rer Nat Demmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE4010536A priority Critical patent/DE4010536A1/de
Priority to PCT/EP1991/000578 priority patent/WO1991015202A1/de
Priority to US07/930,592 priority patent/US5324749A/en
Priority to EP91906603A priority patent/EP0523086A1/de
Priority to AU75503/91A priority patent/AU7550391A/en
Priority to JP91506805A priority patent/JPH05505813A/ja
Publication of DE4010536A1 publication Critical patent/DE4010536A1/de
Application granted granted Critical
Publication of DE4010536C2 publication Critical patent/DE4010536C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE4010536A 1990-04-02 1990-04-02 Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure Granted DE4010536A1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE4010536A DE4010536A1 (de) 1990-04-02 1990-04-02 Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
PCT/EP1991/000578 WO1991015202A1 (de) 1990-04-02 1991-03-26 Pharmazeutische wässrige lösung von 4-[2-(benzolsulfonylamino)-ethyl]-phenoxyessigsäure
US07/930,592 US5324749A (en) 1990-04-02 1991-03-26 Pharmaceutical aqueous solution of 4-[2-(benzene-sulphonylamino)-ethyl]-phenoxyacetic acid
EP91906603A EP0523086A1 (de) 1990-04-02 1991-03-26 Pharmazeutische wässrige lösung von 4- 2-(benzolsulfonylamino)-ethyl]-phenoxyessigsäure
AU75503/91A AU7550391A (en) 1990-04-02 1991-03-26 Pharmaceutical aqueous solution of 4-{2-(benzolsulphonylamino)-ethyl}-phenoxyacetic acid
JP91506805A JPH05505813A (ja) 1990-04-02 1991-03-26 ４―［２―（ベンゼンスルホニルアミノ）―エチル］―フェノキシ酢酸の医薬用水溶液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4010536A DE4010536A1 (de) 1990-04-02 1990-04-02 Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure

Publications (2)

Publication Number Publication Date
DE4010536A1 true DE4010536A1 (de) 1991-10-10
DE4010536C2 DE4010536C2 (https=) 1992-05-07

Family

ID=6403562

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4010536A Granted DE4010536A1 (de) 1990-04-02 1990-04-02 Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure

Country Status (6)

Country Link
US (1) US5324749A (https=)
EP (1) EP0523086A1 (https=)
JP (1) JPH05505813A (https=)
AU (1) AU7550391A (https=)
DE (1) DE4010536A1 (https=)
WO (1) WO1991015202A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499142A3 (en) * 1991-02-09 1993-05-05 Hoechst Aktiengesellschaft Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs
CA2136007C (en) * 1993-03-17 1999-12-14 Kiyoaki Katano Novel compound with platelet aggregation inhibitor activity
JP5185488B2 (ja) * 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ，インコーポレーテッド ２−（４−イソブチルフェニル）プロピオン酸の医薬組成物
US6727286B2 (en) 2001-11-02 2004-04-27 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
US6806291B1 (en) * 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
CN101189003B (zh) * 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
DE202014105015U1 (de) 2014-10-21 2014-10-29 Ebm-Papst Mulfingen Gmbh & Co. Kg Erdungsvorrichtung

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
GB2054370A (en) * 1979-07-24 1981-02-18 Rosco As Injectable potentiated sulphonamide compositions
US4443477A (en) * 1980-01-07 1984-04-17 Boehringer Mannheim Gmbh Sulphonamidophenylcarboxylic acid compounds and pharmaceutical compositions containing them
EP0265129A1 (en) * 1986-10-09 1988-04-27 Smithkline Beecham Corporation Thrombolytic therapy
US4808627A (en) * 1987-12-16 1989-02-28 E. R. Squibb & Sons, Inc. Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist
EP0309801A2 (en) * 1987-09-17 1989-04-05 E.R. Squibb & Sons, Inc. Use of thromboxane A2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction
EP0325245A1 (en) * 1988-01-19 1989-07-26 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US4820733A (en) * 1988-03-07 1989-04-11 E.R. Squibb & Sons, Inc. Method of preventing or reducing platelet loss during extracorporeal circulation using a thromboxane A2 receptor antagonist

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4258058A (en) * 1978-03-04 1981-03-24 Boehringer Mannheim Gmbh Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition
GB2054370A (en) * 1979-07-24 1981-02-18 Rosco As Injectable potentiated sulphonamide compositions
US4443477A (en) * 1980-01-07 1984-04-17 Boehringer Mannheim Gmbh Sulphonamidophenylcarboxylic acid compounds and pharmaceutical compositions containing them
EP0265129A1 (en) * 1986-10-09 1988-04-27 Smithkline Beecham Corporation Thrombolytic therapy
EP0309801A2 (en) * 1987-09-17 1989-04-05 E.R. Squibb & Sons, Inc. Use of thromboxane A2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction
US4808627A (en) * 1987-12-16 1989-02-28 E. R. Squibb & Sons, Inc. Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist
EP0325245A1 (en) * 1988-01-19 1989-07-26 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use

Also Published As

Publication number Publication date
DE4010536C2 (https=) 1992-05-07
EP0523086A1 (de) 1993-01-20
WO1991015202A1 (de) 1991-10-17
AU7550391A (en) 1991-10-30
JPH05505813A (ja) 1993-08-26
US5324749A (en) 1994-06-28

Similar Documents

Publication Publication Date Title
EP0242328B1 (de) Arzneimittel zur Behandlung von Entzündungen im Auge
DE4340781C3 (de) Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DE69223624T2 (de) Taxan-derivate enthaltende arzneimittel
DE3924207C2 (https=)
EP1206244B1 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
DE4010536C2 (https=)
EP0580685B1 (de) Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
DE69808793T2 (de) Pharmazeutische zusammensetzungen aus dalfopristine und quinupristine und verfahren zu ihrer herstellung
DE2611183A1 (de) Stabile dosierungsform von prostaglandinartigen verbindungen
US5276044A (en) Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
DE19833119A1 (de) Spritzfertige Injektionslösungen enthaltend Carvedilol
DE4220616C2 (de) Dexniguldipin zur intravenösen Verabreichung
DE2937290A1 (de) Etomidate enthaltende injektionspraeparate zur intravenoesen verabfolgung
DE2723936A1 (de) Ophthalmische loesung fuer die glaucom-behandlung
EP2142169A2 (de) Wässrige pharmazeutische zubereitung
DE69426295T2 (de) Organkonservierungsmittel
EP0656777B1 (de) Spritzfertige azosemid-injektionslösungen
DE102006031175A1 (de) Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
DE2538678A1 (de) Injizierbare loesungen
DE2556001C3 (de) Spritzfertige injizierbare Lösungen mit einem Gehalt an Alkalicanrenoat
EP0036514B1 (de) Verwendung eines aus Blutserum gewonnenen Wirkstoffes zur Stabilisierung von Prostaglandinen
EP3328356A1 (de) Konzentrat enthaltend alprostadil
EP0051163A2 (de) Intramuskulär schmerzlos anwendbare 4-Dimethylaminophenol Hydrochlorid-Lösung und Verfahren zu deren Herstellung
DE3801178A1 (de) Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
DE1617433C (de) Verfahren zur Herstellung von 5,5 Diphenyl hydantoin Natrium Losungen fur Injektionszwecke

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee